Clalit Is Israel's Largest Buyer of Healthcare AI

Nearly 5 million members. 14 hospitals. ~1,500 clinics. Three decades of digitized records. The largest payer-provider system in Israel is also its single biggest healthcare-AI customer.

Clalit is Israel's largest buyer of healthcare AI.

Nearly 5 million members. Roughly 52% market share. 14 hospitals. ~1,500 primary care clinics. ~35,000 employees. 30+ years of fully digitized records. The largest integrated payer-provider in the developed world by national share — and the single most important buyer in Israeli healthtech.

That last sentence is almost never written.

Why It Matters

Clalit is the binary commercial credential in Israeli healthtech. A Clalit contract is, in effect, a national-scale clinical-deployment proof point — the kind no U.S. system can match without a decade of integration work. For foreign acquirers screening Israeli targets, "Has Clalit deployed it?" is increasingly the diligence question that decides the price. For founders, it is the credential that decides the next round.

The Israeli healthtech sector is described, fundraised, and acquired through its startups. The startups are real. But sitting above them — buying, piloting, validating, and shaping their roadmaps — is a single payer-provider with a hospital footprint, a research institute ranked among the strongest in the world, and a data asset that pharma multinationals fly in to negotiate access to.

This is what that buyer looks like.

The Footprint

Clalit operates at a scale that has no domestic peer.

14 hospitals — about 30% of Israel's acute-care beds.
~1,500 primary care clinics, plus pharmacies and dental clinics.
~35,000 employees — doctors, nurses, pharmacists, paramedics, technicians, administrators.
>95% five-year member retention, by Clalit's own published figures. Members rarely leave.

Translation: a captive, longitudinal, vertically integrated population. The kind of population a U.S. health system spends a decade building through acquisitions — and then doesn't fully consolidate.

The Data Asset

The Clalit dataset is not a marketing claim. It is an operating asset.

More than 30 years of digitized records. Close to 7 million patient records by Clalit's own description. Diagnoses, hospitalizations, clinic visits, demographics, labs, medications (ordered and fulfilled), procedures, registries — linked at the member level.

In the Nordic countries, registries like this took decades of public investment and shape state research agendas. Israel built one inside a payer-provider.

The Clalit Research Institute (CRI), founded in 2010 and a designated WHO Collaborating Center since 2014, runs on top of it. Hundreds of peer-reviewed studies per year. Citations in NEJM, The Lancet, JAMA. First place in the NEJM SPRINT Challenge — a global predictive-modeling competition.

CRI's work is not academic decoration. It feeds operational tools.

AI in Production, Not in Pilot

The headline tool is C-Pi — an AI-powered primary-care platform that flags high-risk patients in real time and surfaces recommended interventions inside the physician's electronic health record.

Already, more than 1,000 Clalit primary-care doctors receive AI-driven recommendations daily, by Clalit's own description, delivered through C-Pi and adjacent decision-support layers.

Predictive models embedded in care include early-renal-failure prediction up to five years in advance and readmission-risk scoring used to triage hospital discharge planning. Cardiovascular and oncology models follow the same pattern: built on Clalit data, validated on Clalit outcomes, deployed in Clalit clinics.

This is what a buyer looks like. Not a strategy deck. Not an innovation sandbox. Production AI, running on a national patient base.

The International Partners

Clalit's outside partnerships, taken together, form a quiet but visible architecture.

Harvard Medical School — the Ivan and Francesca Berkowitz Family Living Laboratory Collaboration, run with the Clalit Research Institute on precision and predictive medicine.
Charité – Universitätsmedizin Berlin — formal scientific cooperation initiated in 2022, focused on AI-driven care platforms at scale.
IQVIA — first Prime Site in Israel, announced 2022, combining Clalit's real-world data with IQVIA's global clinical-trial network for pharma R&D and RWE studies.
Broad Institute, MIT collaborators — co-authored work in precision medicine and population genomics.

Each of these is a deal. Each one was negotiated. Each one is a vote on the dataset's value.

The Spinout Pipeline Nobody Tracks

Clalit Innovation has been formally operating as the system's commercial innovation arm since 2017.

Its mandate spans three flows that rarely sit inside the same organization:

Inbound vendor evaluation. Startups pitch, pilot, and contract with Clalit at the system level. A national HMO deployment is a serious commercial credential.
Internal R&D. CRI builds. Clalit's digital division productizes. Tools ship to clinics.
Spinout activity. Several companies — across telemedicine, oncology decision support, and chronic disease management — trace their origin to Clalit-internal R&D or Clalit data partnerships.

There is no public registry of these companies. No standard "Clalit alumni" tracker. The result: a multi-hundred-million-dollar innovation pipeline operating substantially outside the field of view of foreign investors.

The Investor Layer

For foreign acquirers screening Israeli healthtech targets, the question that decides the deal is increasingly the same.

Has Clalit deployed it?

A Clalit contract is, in effect, a national-scale clinical-deployment credential. A population validation layer that no U.S. system can match without years of integration work. For acquirers, a startup with a real Clalit deployment is a different asset class than one without.

That credential is decided inside one institution. By a small number of operators. Mostly in Hebrew. Almost never reported in English.

The Leadership

The most internationally visible figure is Prof. Ran Balicer, Clalit's Chief Innovation Officer and the founding director of the Clalit Research Institute. Balicer co-chaired Israel's expert COVID-19 advisory panel, holds a visiting professorship at Charité, and is among the most cited Israeli public-health and AI-in-medicine figures globally.

Behind him sits an institutional bench — clinicians who run districts, data scientists who run models, and procurement leaders who decide what gets bought — that is structurally invisible to the global business press.

When global pharma negotiates Israel-wide access, it starts here.

When a healthtech startup wants the deployment that decides its next round, it pitches here.

When the WHO benchmarks data-driven primary care, it cites here.

Clalit is Israel's largest buyer of healthcare AI.